Loading...

Sorrento Therapeutics, Inc.

SRNE•NASDAQ
Healthcare
Biotechnology
$0.002
$-0.00(-20.00%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Financial performance has remained strong, with revenue growing from $17.40M in Q3 2022 to $15.03M in Q2 2023. Gross profit continued to perform well, with margins at 44% in the latest quarter. Operating income reached -$77.23M in Q2 2023, holding a steady -514% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$99.48M. Net income rose to -$95.21M, keeping EPS at -$0.17. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;